Search

for
Search:

Community Join

2 / 1000+ results

community Coegin Pharma to release Follicopeptide (FOL005) by Q2 2025

118 upvotes 2 years ago

Follicopeptide (FOL005) by Coegin Pharma will launch as a cosmetic hair growth treatment by Q2 2025, showing similar efficacy to finasteride. Users discuss the benefits and skepticism of releasing hair loss treatments as cosmetics rather than drugs.

community Today I received my first Batch Follicopeptide

in Treatment 139 upvotes 7 months ago

A user purchased an expensive hair loss treatment called Follicopeptide, which many others in the conversation believe to be a scam, suggesting instead the use of proven treatments like minoxidil and finasteride. Some users report positive effects from Follicopeptide, but skepticism remains high due to lack of transparency about its ingredients and the company's credibility.

View more "follicopeptide" in community →

Learn

7 / 801 results

learn Follicusan

learn Follistatin

glycoprotein that inhibits TGF-β and promotes hair growth by antagonizing activin

What is follistatin, and how does it influence hair follicle growth and regeneration? Follistatin blocks activin and related growth-inhibiting proteins, which in laboratory and animal work is described as keeping hair follicles in their growth phase; the only verifiable human evidence is a single small 2011 phase 1 injection trial, so follistatin remains experimental and is not an approved hair-loss treatment.

learn Pea peptides

learn PP405

Did you know PP405 peptides can help protect your follicles from DHT? PP405 is not a peptide and does not block DHT: it is an experimental topical gel from Pelage Pharmaceuticals that inhibits the mitochondrial pyruvate carrier, aimed at waking dormant follicles. Its registered Phase 2 trial (NCT06393452) measured safety and tolerability in 78 adults with pattern hair loss; it is not approved and not for sale.
Got small bald patches they say are from stress? PP405 sprays could help bring them back to life. PP405 is an experimental topical gel from Pelage Pharmaceuticals that inhibits the mitochondrial pyruvate carrier; its registered Phase 2 trial (NCT06393452) tested it once daily in 78 adults with pattern hair loss, for safety and tolerability. It is not approved, not for sale, and has not been studied in alopecia areata or stress-related shedding.

learn oligopeptide-71

learn octapeptide-2

learn sh-Polypeptide-7

How does sh-Polypeptide-7 help stimulate hair follicle activity or reduce scalp inflammation? sh-Polypeptide-7 is the INCI name for a lab-made form of human growth hormone (somatotropin) — not EGF, which is sh-Oligopeptide-1. Growth hormone and IGF-1 signalling is documented in hair follicle biology, but there is no published human trial of sh-Polypeptide-7 applied to the scalp for hair growth or scalp inflammation.

View more "follicopeptide" in learn →

Research

5 / 1000+ results

research An osteopontin‐derived peptide inhibits human hair growth at least in part by decreasing fibroblast growth factor‐7 production in outer root sheath keratinocytes

19 citations , September 2019 in “British Journal of Dermatology”

This study found that a novel peptide, FOL-005, derived from osteopontin, significantly inhibited hair growth in human hair follicles both ex vivo and in vivo, suggesting potential as a treatment for unwanted hair growth.

research Osteopontin regulatory functions in the hair follicle open a therapeutic approach for hypertrichosis

November 2019 in “British Journal of Dermatology”

FOL-005 peptide may help treat excessive hair growth safely.

FGF7-Dependent Inhibition of Human Hair Growth by an Osteopontin-Derived Peptide: A Novel Solution for Hirsutism and Hypertrichosis

research 1371 FGF7-dependent inhibition of human hair growth byan osteopontin-derived peptide: A novel solution for hirsutism and hypertrichosis?

April 2018 in “Journal of Investigative Dermatology”

This study identified the osteopontin-derived peptide, FOL-005, as a potential inhibitor of unwanted human hair growth by promoting catagen development without reducing stem cell numbers or showing toxicity.

Using MALDI-MSI Analysis to Study Distribution of FOL-005, a Potent, Novel Inhibitor of Human Hair Growth, After Subcutaneous Injection in Mice

research 695 Using MALDI-MSI analysis to study distribution of FOL-005, a potent, novel inhibitor of human hair growth, after subcutaneous injection in mice

April 2016 in “Journal of Investigative Dermatology”

This study found that a newly developed peptide, FOL-005, significantly inhibited hair growth and counteracted minoxidil's effects in organ-cultured human male scalp skin and mouse models, without apparent toxicity.

Analysis of Mice Skin Distribution Using MALDI-MSI After Subcutaneous Injections of a Potent Novel Peptide Hair Growth Promoter, FOL-005

research 128 Analysis of mice skin distribution using MALDI-MSI after subcutaneous injections of a potent novel peptide hair growth promoter, FOL-005

April 2018 in “Journal of Investigative Dermatology”

In a clinical phase I/IIa study, subcutaneous injections of the peptide FOL-005 increased hair growth by 8% and were safe for treating alopecia.

View more "follicopeptide" in research →

Experts

— no results

Try a deeper search in experts →

Clinics

— no results

Try a deeper search in clinics →